Sunday, October 25, 2020
Home Tags ESMO

Tag: ESMO

2020 ESMO Recap: Oncology Community Unites to Bring Innovation to Patients...

The European Society for Medical Oncology (ESMO) recently hosted its annual congress, remaining dedicated to supporting oncology professionals to ensure patients with cancer are...

ESMO Virtual Congress 2020: Treatment in CARD Eligible Metastatic Castration Resistant...

(UroToday.com) The CARD trial was a randomized open-label study of cabazitaxel versus the alternative anti-androgen therapy in patients with metastatic castration resistant prostate cancer (mCRPC)...

NuCana Presents Three Posters at the ESMO Virtual Congress 2020 Nasdaq:NCNA

Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302) NUC-3373’s...

ESMO 2020: Two-pronged attack using new targeted drug could treat ‘addicted’...

Image: Clinical trials pharmacy. Credit: Jan Chlebik for the ICR An experimental cancer drug used alongside targeted hormone treatment could treat an aggressive group of...

ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga

Roche has shared phase 3 data on the drug that enhanced the efficacy of Johnson & Johnson’s Zytiga in a subset of prostate cancer...

Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 1 Clinical Study...

Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 1 Clinical Study Evaluating Investigational Agent Dubermatinib in Patients with Advanced Solid Tumors at ESMO 2020...

ESMO Virtual Congress 2020: Pembrolizumab plus Enzalutamide in Patients with Abiraterone...

(UroToday.com) The PD-1 inhibitor pembrolizumab has shown antitumor activity in patients with heavily pre-treated, PD-L1-positive advanced prostate cancer and in PD-L1-positive and PD-L1-negative patients...

ESMO: New Trodelvy breast, bladder cancer data show why Gilead’s going...

Compared with the spate of multibillion-dollar buyouts last year, biopharma M&A has been relatively quiet in 2020—until last week, when Gilead Sciences surprised the market...

ESMO: Pfizer’s Ibrance flop in early breast cancer shouldn’t hurt metastatic...

Pfizer talked up Ibrance’s potential in early breast cancer for years before getting the bad news this May: The Pallas study, examining the drug...
20,764FansLike
2,400FollowersFollow
16,600SubscribersSubscribe

EDITOR PICKS